Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

GambitBio: empowering early detection at home

GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. CRUK recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.

Tiffany began her PhD in The Department of Oncology in 2018. GambitBio was launched in 2023 as part of her entry for University of Oxford’s All-Innovate business idea competition.

Speaking to CRUK about the venture, Tiffany said: 'GambitBio exists to push for early detection and reduce the number of cancer-related deaths. We want people to be able to detect what is wrong earlier so clinicians can intervene and treat the problem sooner. Early detection can give people up to 95% survival rate over a 10-year period for certain cancer types.'

Read the full interview with Tiffany on the Cancer Research Horizon's website. 

Similar stories

Blood tests could identify early signs of cancer years before diagnosis

A study of blood samples collected up to nine years before a cancer diagnosis found changes in the DNA that captured the body’s response to early traces of cancer development. The findings, which are published in Cell Genomics, build on other recent work by researchers at Oxford Population Health and the University of Toronto aimed at identifying the earliest signs of cancer development using highly sensitive blood profiling that captures DNA changes.

Fallopian tube immune cells could offer new route to prevent and treat ovarian cancer

Research led by Professor Ahmed Ahmed and Dr Nancy Zaarour has identified a population of immune cells in the fallopian tubes that can recognise ovarian cancer cells, raising the possibility of harnessing the body's early immune defences to develop new ways to prevent or treat the disease.

[Video] Cancer vaccines: responding to the early red flags

Making cancer curable is undoubtedly one of the biggest medical challenges we face. But what if we could actually prevent cancer from taking hold in the first place? That’s what Professor David Church and his team in the Centre for Human Genetics at the University of Oxford are investigating.

WE WANT TO HEAR YOUR NEWS

Publishing a paper? Just won an award? We can help promote your news and elevate the overall impact of your work.

Contact us at cancer@medsci.ox.ac.uk.

Similar Stories

Blood tests could identify early signs of cancer years before diagnosis

A study of blood samples collected up to nine years before a cancer diagnosis found changes in the DNA that captured the body’s response to early traces of cancer development. The findings, which are published in Cell Genomics, build on other recent work by researchers at Oxford Population Health and the University of Toronto aimed at identifying the earliest signs of cancer development using highly sensitive blood profiling that captures DNA changes.

Fallopian tube immune cells could offer new route to prevent and treat ovarian cancer

Research led by Professor Ahmed Ahmed and Dr Nancy Zaarour has identified a population of immune cells in the fallopian tubes that can recognise ovarian cancer cells, raising the possibility of harnessing the body's early immune defences to develop new ways to prevent or treat the disease.

[Video] Cancer vaccines: responding to the early red flags

Making cancer curable is undoubtedly one of the biggest medical challenges we face. But what if we could actually prevent cancer from taking hold in the first place? That’s what Professor David Church and his team in the Centre for Human Genetics at the University of Oxford are investigating.